Mutations in PIK3CA, the gene encoding the p110a catalytic subunit of phosphoinositide 3-kinase (PI3K), have been shown to transform mammary epithelial cells (MEC). Studies suggest this transforming activity requires binding of mutant p110a via p85 to phosphorylated YXXM motifs in activated receptor tyrosine kinases (RTK) or adaptors. Using transgenic mice, we examined if ErbB3, a potent activator of PI3K, is required for mutant PIK3CA-mediated transformation of MECs. Conditional loss of ErbB3 in mammary epithelium resulted in a delay of PIK3CA
Introduction
Phosphoinositide 3-kinase (PI3K) is the most frequently mutated signaling pathway in cancer, affecting tumor cell survival, proliferation, migration, and metabolism (1, 2) . PI3K is a lipid kinase composed of a p85 regulatory subunit dimerized with a p110 catalytic subunit (1, 3) . The N-terminal SH2 domain of p85 binds to phosphorylated tyrosines in receptors or adaptors; this binding relieves the p85-mediated inhibition of p110 that, as a result, becomes activated and catalyzes the conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), a second messenger that recruits signal transducers (Akt, PDK1, SGK, etc.) to the plasma membrane, where they become activated (1) .
The PI3K pathway is aberrantly activated by gain-of-function mutations in p110a (PIK3CA) and p85a (PIK3R1), amplification of wild-type PIK3CA, p110b (PIK3CB), and PDK1, loss/ inactivation of the PIP3 phosphatases PTEN and INPP4B, mutation and/or amplification of AKT1-3, and amplification of receptor tyrosine kinases (RTK; refs. 4, 5) . Three "hotspot" mutations have been identified in PIK3CA: E542K, E545K, and H1047R, accounting for approximately 80% of PIK3CA mutations (2, 6, 7) . PIK3CA mutations occur in approximately 40% of breast cancers, mainly in tumors with luminal and HER2-enriched gene expression (8) , where they have been associated with a more virulent phenotype and resistance to antiestrogen and anti-HER2 therapy.
HER2/ErbB2 gene amplification occurs in 25% of breast cancers where it associates with poor patient outcome. The main dimerization partner of HER2 is HER3/ErbB3. Six p85-binding motifs in ErbB3 activate PI3K (9, 10) . ErbB3 is essential for PI3K activation and survival of HER2-overexpressing breast cancer cells (9, 11, 12) . Therapies that inhibit PI3K induce ErbB3 expression and reactivation via feedback mechanisms, which partially maintain PI3K and counteract drug action. As such, the efficacy of HER2 and PI3K inhibitors is improved by coinhibition of ErbB3 (11, 13, 14) .
In addition to ErbB2/ErbB3, other RTKs activate PI3K via insulin receptor substrate (IRS) and Gab family molecules. These adaptors lack enzymatic activity, but when tyrosine phosphorylated by RTKs, they recruit p85 (PI3K) and other signaling molecules (15, 16) . Activated RTKs, including insulin and insulin-like growth factor (IGF) receptors, VEGF receptor (VEGFR), EGF receptor (EGFR), and ALK recruit IRS adaptors (16, 17) . IRS-1 has 9 p85-binding motifs (18) and, like ErbB3, strongly activates PI3K. Similarly, Gab1 and Gab2 contain 3 p85-binding motifs and are tyrosine phosphorylated by ErbB2, MET, Abl, FGFR, EGFR, and Src kinases (15) . The p85 subunit was discovered by its association with platelet-derived growth factor receptor (PDGFR), a potent activator of PI3K (19) . Biochemical analyses have shown that both PIK3CA E545K and PIK3CA
H1047R exhibit approximately 2-fold higher catalytic activity than wild-type PI3K. The association of PIK3CA
H1047R
with PDGFR or IRS-1 phosphopeptides further increases the catalytic activity of the mutant enzyme (20) . In addition, PIK3CA
H1047R association with p85 is required for transformation induced by mutant PI3K (6, 21) . These data suggest a role for upstream RTKs in the signaling output of mutant PI3K, leading us to hypothesize that mutant PIK3CA requires upstream adaptors, such as ErbB3, to induce epithelial transformation and tumor progression.
We show herein that mammary gland hyperplasia induced by temporally regulated expression of mutant PIK3CA was delayed in mice lacking ErbB3 in the mammary epithelium. In contrast, tumor formation and PI3K activity were unaffected by ErbB3 ablation. In tumors expressing ErbB3, mutant PI3K associated with several tyrosine-phosphorylated proteins, including ErbB3. In tumors lacking ErbB3, PI3K still associated with other upstream adaptors and RTKs. Inhibition of RTKs or adaptors known to activate PI3K did not block cell growth or PI3K activity in mammary tumors or PIK3CA-mutant human breast cancer cells. However, simultaneous inhibition of upstream RTKs and mutant p110a more potently inhibited tumor growth and PI3K signaling than inhibition of p110a alone. These data suggest that mutant PIK3CA still relies upon upstream activators and combined inhibition of PI3K and these activators is a rational treatment strategy against tumors harboring PIK3CA-activating mutations.
Materials and Methods

Cell culture
MDA-MB-453 and T47D cells were from American Type Culture Collection. MDA-MB-453 were authenticated in March 2013 by short tandem repeat DNA analysis (DDC Medical); authentication of T47D cells (March 2011) has been described previously (22) . CAL-148 and BT20 cells were provided and authenticated as described previously (23) . All cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS (Life Technologies). EZN-3920 and EZN-4455 are locked nucleic acid (LNA) antisense molecules provided by Enzon Pharmaceuticals (11, 24) ; they were resuspended in sterile PBS to a stock concentration of 5 mmol/L and applied to cells at 5 mmol/L in the absence of transfection reagent. EZN-3920 targets ErbB3 and EZN-4455 is a scrambled control antisense. BYL719 (25) and LJM716 (26) , provided by Novartis, were resuspended to a stock concentration of 1 mmol/L in dimethyl sulfoxide (DMSO) or 10 mg/mL in sterile PBS, respectively. siRNA (Qiagen) were transfected at a final concentration of 50 nmol/L total siRNA using Lipofectamine RNAiMAX (Life Technologies) following the manufacturer's protocol (see Supplementary Methods). The duration and concentration of each drug or siRNA treatment is described with each figure. Media and inhibitors were replenished every 3 days. Colony growth was assessed by plating cells and staining with crystal violet as detailed in Supplementary Methods.
Mice
To generate the iPIK3.iCre.ErbB3 FL/FL model on a congenic FVB background, the following FVB mouse strains were interbred: MMTV-rtTA (27) , Tet-Op-HA-PIK3CA
H1047R -IRES-Luc (28), Tet-Op-Cre (29) , and ErbB3 FL/FL (30) as described in Supplementary Methods. Details of tumor transplantation are also provided in Supplementary Methods. Briefly, harvested tumors were homogenized in serumfree media with gentleMACS C Tubes (Miltenyi Biotec) and resuspended in 7 mL Matrigel diluted with 50% PBS. Tumor homogenates (100 mL) were injected into both inguinal (#4) mammary fat pads of 4-week-old female athymic mice (Harlan Laboratories) using a 25-gauge needle. When tumors reached 125 mm 3 , mice were randomized to 4 treatment groups as indicated in figure legends. Lapatinib di-p-toluenesulfonate salt and imatinib methanesulfonate salt were purchased from LC Laboratories. Lapatinib, imatinib, and BYL719 were resuspended in 0.5% methyl cellulose, 0.1% Tween-80 for treatment by orogastric gavage. Lapatinib and imatinib were administered twice daily at 100 mg/kg/dose and BYL719 once daily at 30 mg/kg/dose. In the first study, all mice were sacrificed when tumors in vehicle-treated mice exceeded 1.5 cm 3 . In the second study, animals with tumors greater than 1.0 cm 3 were sacrificed and all remaining animals were sacrificed on day 21. Mice were always sacrificed 1 hour after drug treatment.
Protein and histologic analyses
Cell line and tumor protein lysates were prepared as described in Supplementary Methods. Immunoprecipitation was conducted with a p85 (Millipore) or a hemagglutinin (HA) antibody (Cell Signaling Technology) using a ratio of 1 mg antibody: 250 mg lysate: 5 mL Dynal protein G beads (Life Technologies) with end-over-end rotation at 4 C for 4 hours. For immunoblot analysis, equal amounts of protein/lane were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and analyzed with antibodies as described in Supplementary Methods. Phospho-RTK arrays were purchased from R&D Systems and incubated with 225 mg cell lysates following manufacturer's directions. Details of guinea pig anti-cytokeratin 8 (RDI-Fitzgerald) and rabbit anti-cytokeratin 5 (Covance) immunofluorescent staining of tissue sections and hematoxylin staining of whole mount mammary glands are provided in Supplementary Methods.
Gene expression analyses
Tumor RNA was harvested from ErbB3 FL/þ and ErbB3 FL/FL iPIK3.iCre tumors and analyzed by cDNA microarray as described previously (31, 32) . Briefly, RNA isolated by Qiagen RNeasy mini kit was hybridized to Agilent custom 4 Â 180 K microarrays as previously described (31); the signal from iPIK3. Cre RNA was normalized to the Herschkowitz and colleagues murine dataset (32) . The mutant PIK3CA gene signature (33) was calculated for every genotype in the Herschkowitz and colleagues mouse tumor dataset (32) and the iPIK3.iCre tumors. The average gene signature scores for each tumor class were plotted as boxplots to compare mutant PIK3CA-induced gene expression across previously defined classes (32) .
Statistical analyses
Significant differences (P < 0.01) were determined by ANOVA and Bonferroni post hoc tests (multiple testing-corrected) or Student t test using Graphpad Prism software.
Results
ErbB3 inhibition sensitizes mutant PIK3CA breast cancer cells to a p110a inhibitor
ErbB3 silencing impairs the proliferative advantage conferred by mutant PIK3CA in HER2-amplified breast cancer cells (34) . However, the impact of ErbB3 in PIK3CA-mutant breast cells lacking HER2 amplification is less clear. We treated, MDA-MB-453, T47D, BT20, and CAL-148 breast cancer cells, all harboring PIK3CA
H1047R
, with the ErbB3-neutralizing antibody, LJM716 (26) , and BYL719, a p110a-specific inhibitor with an IC 50 against wild-type and mutant p110a of 5 nmol/L (25) . BYL719 decreased the proliferation (Fig. 1A-D) and Akt phosphorylation ( Fig. 1E-H ) of all 4 cell lines in a dose-dependent fashion, suggesting p110a
H1047R is a driver of proliferation and PI3K activity in these cells. LJM716 reduced basal and BYL719-induced total and Y1289-P-ErbB3 ( Fig. 1E-H ) and enhanced BYL719-mediated growth inhibition in each cell line ( Fig. 1A-D) , albeit weakly in T47D and CAL-148 cells. We also used EZN-3920, a LNA ErbB3-targeted antisense or a scrambled control LNA antisense, EZN-4455 (11, 24) , in combination with BYL719. EZN-3920 did not reduce ErbB3 expression in MDA-MB-453 or T47D cells (Fig. 1I ). EZN-3920 reduced ErbB3 levels and BYL719-induced Y1289-P-ErbB3 in both BT20 and CAL-148 cells ( Fig. 1L and M) . The combination of BYL719þEZN-3920 exhibited a better antiproliferative effect than either agent alone ( Fig. 1J and K) . In addition, increased T308-P-Akt induced by EZN-3920 was abrogated by BYL719 ( Fig. 1L and M). These data suggest that coinhibition of ErbB3 and p110a impairs the proliferative advantage conferred by mutant PIK3CA in breast cancer cells without HER2 gene amplification.
Loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA, but does not delay tumor formation
To evaluate whether ErbB3 is required for PIK3CA H1047R -induced mammary epithelial cell (MEC) transformation in vivo, we generated transgenic mice in which doxycyclineinduced PIK3CA
H1047R drives mammary tumor formation in the presence or absence of ErbB3. These mice expressed 3 transgenes [MMTV-rtTA (27) , Tet-Op-HA-PIK3CA H1047R -IRESLuc (28), and Tet-Op-Cre (29)] and harbored homozygous or heterozygous floxed ERBB3 alleles (Supplementary Fig. S1 ; refs. 11, 30, 35) . In this model, referred to as iPIK3.iCre, doxycycline treatment simultaneously induced the expression of hemagglutinin-tagged PIK3CA H1047R and Cre recombinase in the mammary epithelium, resulting in Cre-mediated recombination of floxed ERBB3 alleles in MECs expressing PIK3-CA H1047R . The internal ribosomal entry site (IRES)-Luciferase allows bioluminescent detection of cells/tissues expressing PIK3CA H1047R . The mammary ductal epithelium in 6-week-old ErbB3 FL/þ (control) animals extended distally past the central lymph node, whereas the epithelium of ErbB3 FL/FL mice was maintained proximal to the lymph node (Supplementary Fig. S2A ; ref. 36 ). At 9 weeks, the ErbB3 FL/FL ductal epithelium extended past the lymph node, but remained shorter than that of ErbB3 FL/þ animals ( Supplementary Fig. S2B ). Mammary ductal hyperplasia (induced by mutant PIK3CA) was not apparent in either group at 6 or 9 weeks of age (Supplementary Fig. S2A and S2B ). By 12 weeks, ErbB3
FL/þ glands exhibited thickened, irregular ductal epithelium indicative of hyperplasia. However, ErbB3
FL/FL iPIK3.iCre glands contained smooth, normal-appearing ducts ( Fig. 2A and Supplementary Fig. S2C ). Quantitation of epithelial content in whole mounts showed that ErbB3 FL/þ glands contained 80% more epithelium than ErbB3 FL/FL glands ( Fig. 2A) . Histologic examination of mammary gland sections from 12-week-old animals showed that the ErbB3 FL/þ iPIK3.iCre glands contained multiple cell layers of ductal epithelium, whereas the ErbB3 FL/FL iPIK3.iCre epithelium was arranged in a single, smooth cell layer (Fig. 2B ).
Mice were monitored for expression of PIK3CA-IRES-Luciferase by IVIS bioluminescence imaging ( Supplementary Fig.  S3 ). Tumor formation was monitored by mammary gland palpation through 600 days of age. Mice lacking the iPIK3 transgene or not induced with doxycycline failed to develop tumors or exhibit luciferase activity at any point. (Fig. 2D) .
Global gene expression patterns in ErbB3-deficient and -competent tumors were assessed using cDNA microarrays.
Unsupervised, hierarchical cluster analysis of iPIK3 tumors and 13 other genetically engineered mouse models (GEMM) of breast cancer (31, 32) (33) showed that the PIK3CA signature was higher in the iPIK3.iCre models as compared with the other models (Fig.  2F) , consistent with activation of the PI3K pathway. The Loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA, but does not delay tumor formation or alter PI3K signaling or gene expression. A, whole mount inguinal mammary glands from 12-week-old ErbB3 FL/þ and ErbB3 FL/FL iPIK3.iCre mice were stained and photomicrographed at Â40 power (top) followed by conversion to binary pictures (bottom). The average percentage of area occupied by epithelium AESEM was quantitated from 4 representative binary photomicrographs (n ¼ 3 per genotype; right). Ã , P < 0.01. B, representative hematoxylin and eosin-stained sections of mammary glands harvested from 12-week-old ErbB3 FL/þ and ErbB3 FL/FL iPIK3.iCre mice photomicrographed at Â400 power. C, Kaplan-Meier analysis of tumor-free survival of 11 ErbB3
FL/þ and 13 ErbB3 FL/FL iPIK3.iCre mice. Average tumor latency ¼ T 50 . P value calculated using log-rank test. D, lysates were prepared from tumors harvested from 1 ErbB3
, and 4 ErbB3 FL/FL iPIK3.iCre mice and were subjected to immunoblot analysis with the indicated antibodies. E, left, unsupervised hierarchical cluster of 6 ErbB3 FL/þ and 6 ErbB3 FL/FL iPIK3.iCre tumors with 13 previously characterized breast cancer GEMMs (32) using all probes with at least an absolute log 2 expression value greater than 2 on at least 3 arrays (2,203 genes). Right, enlargement of the array dendrogram with common murine groups that represent human phenotypes highlighted for reference: MMTV-Neu (luminal), Normal breast, Claudin-low, and C3-Tag (basal-like). Beneath the dendrogram are 20 classic genes that segregate the intrinsic subtypes. The iPIK3.iCre dendrogram is enlarged to discern individual ErbB3 FL/þ and ErbB3 FL/FL tumors. F, genes with a positive fold change in the mutant PIK3CA gene signature of Loi and colleagues (33) were averaged for each tumor in the combined murine dataset. These values were plotted by median expression for the defined murine classes (32) Histologic examination of iPIK3 tumors revealed heterogeneous histopathologies (Supplementary Fig. S4A ). The most frequent histologies were adenocarcinoma and adenocarcinoma with squamous metaplasia. Squamous metaplasia occurred more frequently in ErbB3 FL/FL samples, whereas metaplastic carcinomas and adenomyoepithelioma-like lesions were unique to ErbB3 FL/þ tumors. ErbB3 FL/þ and ErbB3 FL/FL tumors often displayed cribriform architecture, but tumors with papillary architecture occurred more frequently in ErbB3 FL/FL mice and tumors with solid architecture were only seen in ErbB3 FL/þ mice ( Supplementary Fig. S4B ). PIK3CA-mutant mammary tumors have been reported to coexpress both luminal-type (i.e., CK8) and basal-type cytokeratins (i.e., CK5; refs. 37, 38) . This was seen in ErbB3 FL/þ and ErbB3 FL/FL cancers ( Supplementary Fig. S4C ). Thus, loss of ErbB3 did not enrich for either the luminal or basal population. These data are consistent with 2 recent reports (28, 38) .
Mutant p110a binds to ErbB3 and other tyrosinephosphorylated proteins
Because ErbB3 loss did not attenuate iPIK3.iCre tumorigenesis or PI3K signaling, we sought to determine if PIK3CA H1047R engaged other tyrosine-phosphorylated adaptors or receptors.
We detected hemagglutinin-tagged p110a H1047R in p85 immunoprecipitates from ErbB3 FL/þ and ErbB3 FL/FL tumor lysates (Fig. 3A, second and third rows) . ErbB3 also coprecipitated with p85 in ErbB3 FL/þ , but not ErbB3 FL/FL tumors. Several tyrosine-phosphorylated proteins coprecipitated with p85 in ErbB3-deficient tumors (Fig. 3A) . Immunoprecipitation of mutant p110a using an anti-hemagglutinin antibody pulled down p85 and several tyrosine-phosphorylated proteins in ErbB3 FL/þ and ErbB3 FL/FL tumor lysates, including ErbB3 in the ErbB3 FL/þ tumors (Fig. 3B) . p85 or hemagglutinin frequently coprecipitated IRS-1, a known PI3K scaffold (Fig. 3A and B) . ErbB3 FL/FL tumors lacked detectable ErbB3, but expressed EGFR, ErbB2, IRS-1, and Gab1/2 at levels similar to ErbB3 FL/þ tumors (Fig. 3C) . Association of p85 with ErbB3, Gab1, and IRS-1 in iPIK3 tumor lysates (Fig. 3D) suggests that multiple adaptors can simultaneously engage mutant p110a, perhaps rendering ErbB3 dispensable for activity and plasma membrane localization of PIK3CA H1047R . Because the PIK3CA H1047R -mutant human breast cancer cell line T47D requires mutant p110a for growth and Akt phosphorylation ( Fig. 1B and F) , we assessed the requirement for PI3K-activating adaptors. ErbB3 siRNA reduced coprecipitation of ErbB3 with p85, but Gab2 and IRS-1 continued to associate with p85 following ErbB3 depletion (Fig. 4A) . Furthermore, P-Akt levels were sustained following ErbB3 depletion, consistent with maintenance of PI3K signaling. We combined siRNA-mediated knockdown of ErbB3, Gab2, and/ or IRS-1. Despite significant reduction of all 3 PI3K adaptors, Akt remained phosphorylated, suggesting that PI3K activity was not reduced (Fig. 4B) . Similarly, proliferation was not dramatically altered by combined depletion of ErbB3, Gab2, and IRS-1 (Fig. 4C) . These data suggest that because multiple proteins can engage mutant PI3K, depletion of ErbB3, Gab2, and/or IRS-1 is insufficient to reduce PI3K activity of tumors or cells driven by PIK3CA H1047R .
ErbB RTK activity is dispensable in PIK3CA H1047R tumors
To determine whether RTKs other than ErbB3 are activated in iPIK3.iCre tumors, we conducted phospho-RTK arrays. The most prominent tyrosine-phosphorylated RTKs in both ErbB3 FL/þ and ErbB3 FL/FL tumors were ErbB2, EGFR, PDGFR, and macrophage-stimulating protein receptor (MSPR/ Ron; Fig. 5A) . One of the 8 tumors exhibited high P-HGFR, consistent with hepatocyte growth factor receptor (HGFR; MET) amplification previously reported in this model (28) . We speculate the presence of these phosphorylated RTKs, all capable of engaging PI3K, may negate a requirement for ErbB3 in iPIK3 tumors.
To determine if inhibition of EGFR, ErbB2, and PDGFR would inhibit growth of PIK3CA H1047R -expressing mammary tumors, we treated iPIK3.iCre tumor-bearing mice with (i) vehicle; (ii) EGFR/ErbB2 tyrosine kinase inhibitor (TKI) lapatinib; (iii) PDGFR TKI imatinib; and (iv) lapatinib þ imatinib. Tumor growth was delayed by each single inhibitor and the combination (Fig. 5B) . P-ErbB2 and P-EGFR levels were reduced by lapatinib, whereas imatinib inhibited P-PDGFRa and P-PDGFRb (Fig. 5C ). Imatinib-treated tumors exhibited higher levels of P-ErbB2 and P-EGFR, which were abolished in tumors cotreated with lapatinib. Although the combination of imatinib and lapatinib slowed tumor growth and inhibited ErbB/PDGFR phosphorylation, Akt and PDK1 remained phosphorylated in tumors treated with both RTK inhibitors (Fig.  5D ). Pull down of p85 from tumor lysates coprecipitated IRS-1 and Gab1 as well as other tyrosine-phosphorylated proteins primary tumors were applied to phospho-RTK arrays. One representative array of each genotype is presented (top) and enlarged, exposure-matched levels of ErbB2, PDGFRa, EGFR, MSPR, and HGFR are presented (bottom). B, mice bearing !125 mm 3 orthotopically transplanted iPIK3.iCre tumors were treated twice daily (100 mg/kg/dose) by orogastric gavage with vehicle (Veh), lapatinib (Lap), imatinib (Imat), or lapatinib þ imatinib (LþI; 10 tumors/group). Average tumor volume for each group AESEM is plotted against time. Ã , P < 0.01 (vehicle vs. treatment). C, three tumor lysates per group were subjected to immunoprecipitation (IP) with antibodies against ErbB2, EGFR, PDGFRa, or PDGFRb. Antibody pull downs were subjected to immunoblot analysis with a P-Tyr antibody. Membranes were stripped and reprobed to detect the pulled down RTK. D, the same tumor lysates as in C were evaluated by immunoblot analysis with the indicated antibodies.
( Supplementary Fig. S5A and S5B ). These data suggest that mutant PI3K engages multiple upstream adaptors, potentially explaining how it maintains its activity and effect on tumor growth despite inhibition of EGFR, ErbB2, and PDGFR kinases with a combination of small-molecule inhibitors.
Inhibition of PIK3CA
H1047R -driven tumor growth by a p110a inhibitor is enhanced by coinhibition of ErbB2/ EGFR Data shown in Figs. 2C-F, 4 , and 5B-D suggest that targeted inhibition of signaling events upstream of PI3K, including ErbB3, EGFR, ErbB2, PDGFR, Gab2, or IRS-1, is insufficient to silence PI3K activity and tumor growth in PIK3CA H1047R -driven cancers. Furthermore, compensatory upregulation of signaling networks upstream of PI3K can limit the therapeutic response to PI3K inhibitors (13, 39) . To determine if this occurs in tumors that express PIK3CA H1047R as the pathogenic oncogene, we treated iPIK3.iCre tumors with (i) vehicle; (ii) p110a-specific inhibitor BYL719; (iii) lapatinib; or (iv) lapatinib þ BYL719. Although lapatinib slowed tumor growth less effectively than BYL719, the combination of lapatinib þ BYL719 inhibited tumor growth more potently than either agent alone (Fig. 6A) . Lapatinib reduced EGFR, ErbB2, and ErbB3 phosphorylation (Fig. 6B ), but did not decrease P-PDK1 or P-Akt (Fig. 6C) . BYL719 alone decreased P-Akt, but not P-PDK1. In contrast, BYL719 þ lapatinib markedly reduced P-Akt and P-PDK1 levels (Fig. 6C) , suggesting a more potent suppression of PI3K when p110a and EGFR/ErbB2/ErbB3 are inhibited simultaneously. BYL719 þ lapatinib treatment slowed the weight gain of adolescent, tumor-bearing mice compared with mice treated with single agent BYL719 (P < 0.01), but histopathologic analysis revealed no liver damage in any treatment group (Supplementary Fig. S6 ).
To extend these observations, 4 human breast cancer cell lines with PIK3CA
H1047R
, but without HER2 gene amplification (MDA-MB-453, T47D, BT20, and CAL-148), were treated with BYL719 and lapatinib. BYL719 reduced proliferation and P-Akt in all 4 cell lines (Fig. 7) . Lapatinib inhibited basal and BYL719-induced phosphorylation of EGFR, ErbB2, and ErbB3 in each cell line (Fig. 7E-H) . Lapatinib inhibited the proliferation of 2 cell lines as a single agent and aided the antiproliferative action of BYL719 in all 4 cell lines (Fig. 7A-D) . Compared with singleagent treatments, the combination of BYL719 þ lapatinib resulted in more potent inhibition of S473-P-Akt, T308-P-Akt, and P-S6 in MDA-MB-453 cells; S473-P-Akt, P-ERK, and P-S6 in T47D cells; P-PDK1 and P-ERK in BT20 cells; and T308-P-Akt, P-PDK1, and P-ERK in CAL-148 cells (Fig. 7E-H) . Thus, while signaling downstream of PI3K was differentially affected by BYL719 and lapatinib in the 4 human cell lines and iPIK3.iCre transgenic mouse tumors, combined inhibition of p110a and ErbB receptors resulted in a more potent antitumor effect in all 5 PIK3CA H1047R -driven models.
Discussion
PI3K is the most frequently mutated signaling pathway in breast cancer. Most common somatic alterations in this pathway are "hot spot" mutations in the helical and catalytic domains of PIK3CA (8) . Transgenic mice with conditional expression of PIK3CA H1047R in the mammary gland develop mammary cancers (28) . Despite exhibiting a "gain-of-function," Figure 6 . Growth of PIK3CA
H1047R
-driven tumors is inhibited by combined blockade of p110a and ErbB2/EGFR. A, mice bearing !125 mm 3 orthotopically transplanted iPIK3.iCre tumors were treated with vehicle (twice daily), lapatinib (twice daily at 100 mg/kg/dose), BYL719 (once daily at 30 mg/kg/dose), or lapatinib þ BYL719 (LapþBYL; 14-16 tumors/group). Average tumor volume for each group AESEM is plotted against time.
Ã , P < 0.01 reported at earliest significant difference between groups. B, tumor lysates were subjected to immunoprecipitation (IP) with antibodies against EGFR, ErbB2, or ErbB3 and the resulting immune complexes evaluated by immunoblot analysis with a P-Tyr antibody. Membranes were stripped and re-probed to detect the pulled down RTK. C, the same tumor lysates as in B were evaluated by immunoblot analysis with the indicated antibodies. mutant PIK3CA still requires binding via the regulatory subunit p85 to phosphorylated adaptors or receptors. For example, PIK3CA H1047R -mediated transformation of chick embryo fibroblast depends on its interaction with p85 (21) and the catalytic activity of PI3K H1047R is enhanced by coupling to phosphorylated PDGFR or IRS-1 (20) . Furthermore, knockdown of ErbB3 or its ligand heregulin inhibits growth and P-Akt levels in cells expressing PIK3CA H1047R (34) . Tissue-specific deletion of ErbB3 in the mammary gland results in a delay in ductal extension during puberty, increased apoptosis in terminal end buds (TEB) and a reduction in P-Akt (36), suggesting ErbB3-activated PI3K has an important role in mammary gland morphogenesis. Finally, Cre-mediated deletion of ErbB3 prolonged mammary tumor latency, reduced lung metastases and reduced P-Akt levels in mammary tumors driven by polyomavirus middle T oncogene (PyV mT; ref. 11) . In this mouse model, PyV mT-driven tumor formation is highly dependent upon the association of middle T with p85 (40) and this association is lost upon deletion of ErbB3 or inhibition of ErbB3 phosphorylation with the EGFR/ErbB2 inhibitor lapatinib (11) . These data suggest that ErbB3 is a major activator of wild-type and mutant PI3K in normal and transformed MECs. Thus, we examined if ErbB3 was required for MEC transformation by mutant PI3K.
We showed herein that loss of ErbB3 delayed mammary gland hyperplasia induced by mutant PIK3CA, but was dispensable for mammary tumorigenesis. This is in contrast to mammary tumors induced by the ErbB2/Neu transgene where loss of ErbB3 blocks mammary tumorigenesis (35) . Our data are reminiscent of a recent study by Lahlou and colleagues, in which ErbB2/Neu-mediated hyperplasia, but not MEC transformation, was reduced by an ErbB3 mutant incapable of binding to p85 (PI3K; ref. 41) . In tumors expressing the PI3K-uncoupled ErbB3 mutant, ErbB2 and EGFR engaged p85 to maintain PI3K activity. The iPIK3.iCre mice we present herein are phenotypically similar. It is unclear why genetic ablation of ErbB3 inhibits Neu-induced tumor formation (35) , whereas uncoupling PI3K from ErbB3 does not (41) , but the results suggest PI3K-independent functions of ErbB3. Inhibition of EGFR/ErbB2 or PDGFR slowed mutant PIK3CA tumor growth without affecting Akt and PDK1 phosphorylation. This result suggests 2 not mutually exclusive possibilities. First, many RTKs or adaptors might contribute to PI3K activation in tumors harboring PIK3CA mutations. Second, the heightened activity of the PIK3CA H1047R kinase domain mutant (42, 43) allows for this kinase to signal strongly with fewer/no upstream binding partner(s). However, some upstream binding partners are likely needed because structural data suggest that p85 inhibits the catalytic activity of p110 until the p85/ p110 complex binds to consensus phosphotyrosine YXXM motifs in RTKs/adaptors, thus relieving p85-mediated inhibition of p110 (44) . E545K mutation in PIK3CA causes a structural change in the PI3K holoenzyme such that p85 no longer inhibits p110a, resulting in increased PI3K activity (45) , which cannot be further activated by added tyrosine phosphorylated peptides (20) . In contrast, the high kinase activity of H1047R PI3K doubles upon the addition of phospho-PDGFR or phospho-IRS-1 peptides (20) . Finally, the transforming action of PIK3CA H1047R , but not PIK3CA
E545K
, is markedly reduced by loss of p85 binding, suggesting that PIK3CA H1047R requires binding to RTKs/adaptors for full activity (6, 21) .
The driving oncogene in iPIK3.iCre tumors is PIK3CA H1047R , making PI3K the most compelling therapeutic target. As a single agent, the p110a-specific inhibitor BYL719 reduced tumor growth and P-Akt in iPIK3.iCre tumors without effecting P-PDK1. Dual EGFR/ErbB2 and PI3K inhibition reduced P-Akt and P-PDK1 and decreased tumor growth better than either agent alone. These data suggest that while individual inhibition of mutant PI3K and RTKs upstream was insufficient to suppress PI3K activity and growth, ErbB inhibition significantly enhanced the effect of BYL719 against PI3K mutant cancers. This was recapitulated in PIK3CA H1047R human breast cancer cells. We speculate, however, that tumor cells not initially eliminated by combined ErbB and PI3K inhibition may allow mutant PI3K to engage other RTKs and adaptors, eventually allowing tumors to evade the antitumor effect of PI3K inhibitors.
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